tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CYTK Stock Latest News

Cytokinetics’ Aficamten Study: A New Hope for Pediatric Heart Patients
Company AnnouncementsCytokinetics’ Aficamten Study: A New Hope for Pediatric Heart Patients
8d ago
CYTK
Cytokinetics Advances Pediatric Heart Treatment with Aficamten Study
PremiumCompany Announcements
Cytokinetics Advances Pediatric Heart Treatment with Aficamten Study
16d ago
CYTK
Cytokinetics price target lowered to $53 from $71 at JPMorgan
PremiumThe Fly
Cytokinetics price target lowered to $53 from $71 at JPMorgan
2M ago
CYTK
Promising Potential of Aficamten in Hypertrophic Cardiomyopathy Drives Buy Rating for Cytokinetics
PremiumRatings
Promising Potential of Aficamten in Hypertrophic Cardiomyopathy Drives Buy Rating for Cytokinetics
2M ago
CYTK
Cytokinetics price target lowered to $84 from $103 at Mizuho
PremiumThe Fly
Cytokinetics price target lowered to $84 from $103 at Mizuho
2M ago
CYTK
Promising SEQUOIA-HCM Study Data Justifies Buy Rating for Cytokinetics
PremiumRatingsPromising SEQUOIA-HCM Study Data Justifies Buy Rating for Cytokinetics
2M ago
CYTK
Cytokinetics presents additional data related to Aficamten
Premium
The Fly
Cytokinetics presents additional data related to Aficamten
2M ago
CYTK
Cytokinetics Announces Key Decisions at Annual Meeting
Premium
Company Announcements
Cytokinetics Announces Key Decisions at Annual Meeting
2M ago
8K
CYTK
Cytokinetics to host symposium on Contemporary Landscapes in Muscle Biology
PremiumThe Fly
Cytokinetics to host symposium on Contemporary Landscapes in Muscle Biology
2M ago
CYTK
Buy Rating for Cytokinetics Driven by Promising Phase 3 Results of Aficamten in Hypertrophic Cardiomyopathy
PremiumRatings
Buy Rating for Cytokinetics Driven by Promising Phase 3 Results of Aficamten in Hypertrophic Cardiomyopathy
2M ago
CYTK
Promising Phase 3 Results for Aficamten Boost Cytokinetics’ Market Position in Hypertrophic Cardiomyopathy Treatment
PremiumRatings
Promising Phase 3 Results for Aficamten Boost Cytokinetics’ Market Position in Hypertrophic Cardiomyopathy Treatment
2M ago
CYTK
Cytokinetics’ MAPLE Trial Results: Hold Rating Amid Uncertainties in Secondary Outcomes and Market Adoption
PremiumRatings
Cytokinetics’ MAPLE Trial Results: Hold Rating Amid Uncertainties in Secondary Outcomes and Market Adoption
2M ago
CYTK
Cytokinetics’ Promising Phase 3 Trial Results and Market Potential Justify Buy Rating
PremiumRatingsCytokinetics’ Promising Phase 3 Trial Results and Market Potential Justify Buy Rating
2M ago
CYTK
Cytokinetics’ Aficamten Gains Competitive Edge with Successful Phase 3 Study, Strengthening Market Position
Premium
Ratings
Cytokinetics’ Aficamten Gains Competitive Edge with Successful Phase 3 Study, Strengthening Market Position
2M ago
CYTK
Cytokinetics’ Aficamten Shows Promise as First-Line Treatment for oHCM, Earning Buy Rating from Joseph Pantginis
Premium
Ratings
Cytokinetics’ Aficamten Shows Promise as First-Line Treatment for oHCM, Earning Buy Rating from Joseph Pantginis
2M ago
CYTK
Cytokinetics announces results from MAPLE-HCM, met primary endpoint
PremiumThe Fly
Cytokinetics announces results from MAPLE-HCM, met primary endpoint
2M ago
CYTK
Cytokinetics price target lowered to $53 from $55 at Barclays
PremiumThe Fly
Cytokinetics price target lowered to $53 from $55 at Barclays
3M ago
CYTK
Cytokinetics Receives Buy Rating Amid Positive Outlook for Aficamten and Strong Financial Position
PremiumRatings
Cytokinetics Receives Buy Rating Amid Positive Outlook for Aficamten and Strong Financial Position
3M ago
CYTK
Cytokinetics’ Earnings Call: Balancing Progress and Challenges
PremiumCompany Announcements
Cytokinetics’ Earnings Call: Balancing Progress and Challenges
3M ago
CYTK
Cytokinetics Buy Rating: Strategic Developments and Market Opportunities Drive Optimism Despite FDA Delay
PremiumRatingsCytokinetics Buy Rating: Strategic Developments and Market Opportunities Drive Optimism Despite FDA Delay
3M ago
CYTK
Cytokinetics: Strong Financials and Promising Pipeline Drive Buy Rating
Premium
Ratings
Cytokinetics: Strong Financials and Promising Pipeline Drive Buy Rating
3M ago
CYTK
Cytokinetics price target lowered to $80 from $86 at Citi
Premium
The Fly
Cytokinetics price target lowered to $80 from $86 at Citi
3M ago
CYTK

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >